GSK's Shingles Vaccine Steps Closer To Catching Zostavax
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is preparing for major filings next year for its challenger to Sanofi Pasteur MSD's Zostavax shingles vaccine, now named Shingrix (HZ/su vaccine), after promising top-line data in a second Phase III trial confirmed its benefits in an older patient population.
You may also be interested in...
Merck & Co's New Shingles Vaccine Clears First Phase III Hurdle
Merck & Co has positive data from the first of two Phase III trials of its new varicella zoster virus vaccine for the prevention of shingles in immunocompromised patients, but will the product be enough to prop up its waning Zostavax in the face of GSK's Shingrix?
GSK Shingles Vaccine Adds Evidence It Can Outperform Merck’s Zostavax
The strength of more detailed data on GSK’s shingles vaccine in older people from the Phase III ZOE-70 study raises prospects Shingrix can advance into a market that Merck’s Zostavax currently has to itself.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.